FOXO Technologies Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsFOXO Technologies Inc. is a healthcare services and technology company operating rural hospital, behavioral health, biospecimen sourcing, and epigenetic diagnostics divisions.
What they do
The company operates three reportable segments: Healthcare (behavioral health and a critical access hospital), Life Science Services (biospecimen sourcing for biotech and pharma), and Labs (commercializing epigenetic biomarker technology for life insurance underwriting). Healthcare includes Myrtle Recovery Centers (substance use disorder treatment) and Scott County Community Health, doing business as Big South Fork Medical Center, a 25-bed critical access hospital in Oneida, Tennessee. Life Science Services includes Vector BioSource, acquired September 19, 2025. Labs is developing saliva-based epigenetic biomarkers for underwriting risk classification.
Revenue drivers
- Healthcare segment — Includes behavioral health services (inpatient and outpatient substance use disorder treatment) and hospital services (emergency, laboratory, radiology, respiratory, pharmacy). Revenue grew with acquisitions of Myrtle (June 2024) and RCHI/SCCH (September 2024).
- Life Science Services segment — Vector BioSource provides biological materials for research, diagnostics, and therapeutic applications. Acquired September 19, 2025; contributes to recent revenue growth.
- Labs segment — Commercializing epigenetic biomarker technology for life insurance underwriting. Early stage; no significant revenue disclosed in the provided excerpts.
Recent performance
Annual revenue grew from $4.1M in 2024 to $16.4M in 2025. Net loss for 2025 was $-12.4M, consistent with 2024. Operating cash flow was $-3.9M in 2025, slightly worse than $-2.8M in 2024. In the first quarter of 2026, revenue was $5.2M, up from $4.4M in Q4 2025 but down from $5.2M in Q2 2025. As of March 31, 2026, cash and equivalents were $65,896, with total assets of $45.8M and total liabilities of $36.2M.
Strategy
The company is focused on integrating its acquisitions to expand healthcare services, including adding tele-specialty services and cardiac diagnostics at Big South Fork Medical Center. It is pursuing growth in the Life Science Services segment through Vector BioSource. The Labs segment continues to develop epigenetic biomarker products for the life insurance industry. Management is also raising capital and entering material agreements to support operations, as indicated by recent 8-K filings.
Risks
- Limited voting power and control — Series A Preferred Stock holders and RHI control a majority of voting power, which can limit minority shareholders' influence.
- Going concern risk — The company had only $65,896 cash at March 31, 2026, raising substantial doubt about its ability to continue operations without additional financing.
- Integration and acquisition risk — Recent acquisitions of Myrtle, RCHI/SCCH, and Vector may not be fully integrated, and the company may face operational or financial challenges.
- Regulatory and reimbursement risk — Healthcare operations are subject to Medicare cost report settlements and regulatory requirements; changes could impact revenue.
Outlook
Management has not provided explicit forward guidance in the provided excerpts. The company continues to focus on expanding healthcare services and biospecimen sourcing. The Labs segment remains in early commercialization. The company's ability to fund operations depends on raising additional capital.